Alveo Technologies: Shaun Holt, Erik Tyrrell-Knott, and Slava Elagin

Alveo Technologies, an Alameda, California-based developer of point-of-care molecular tests for infectious diseases, has made three new executive appointments: Shaun Holt as CEO and chairman of the board of directors; Erik Tyrrell-Knott as chief business and strategy officer; and Slava Elagin as chief technology officer.

Holt previously served as chief operating officer at Atonarp, an optical and mass spectrometry instrument company. Prior to that he was CFO for Berkeley Lights, leading that company through its $205 million IPO. Holt also held numerous finance leadership positions during a seven-year tenure with Illumina. He is an advisor to Celesta Capital and is on the board of directors of Prellis Biologics.

Tyrrell-Knott most recently served as VP of business development at Atonarp. Prior to that he was head of business development at Thermo Fisher Scientific. Tyrrell-Knott also previously served as senior VP of business development and product management at Mesa Biotech prior to its acquisition by Thermo Fisher.

Elagin has held senior executive operations and R&D positions with several publicly traded and privately held companies including MiraVista Diagnostics, Meridian Biosciences, EraGen Biosciences, and Third Wave Technologies.